Deals, Partnering

BMS, Oncolys ink HIV pact

Posted on 20 December 2010

Tags: ,

Bristol-Myers Squibb and Japan's Oncolys BioPharma have signed a definitive agreement for festinavir, a next-generation, orally available nucleoside reverse transcriptase inhibitor in Phase II development for HIV. See this press release fully categorised, including termsheet of this BMS/Oncolys deal

Print Friendly, PDF & Email

Leave a Reply